Loading
NASDAQHealthcareBiotechnology
Latest quote
$5.27
−$0.22 · -4.01%
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Previous close
$5.27
−$0.22 · -4.01%
After-hours
$5.17
−$0.10 · -1.90%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Day range
Current $5.27
52-week range
Current $5.27
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
33
Expensive
Sentiment
74
Bullish
Risk
80
High Risk
Momentum
39
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Day range
Current $5.27
52-week range
Current $5.27
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 881.71K USD |
| Cost of goods sold | — | 600K USD | — | 1.49M USD | 1.64M USD |
| Gross profit | — | −600K USD | — | −1.49M USD | −757.53K USD |
| Research and development | 70.1M USD | 32.22M USD | 31.17M USD | 16.14M USD | 36.45M USD |
| Selling, general, and administrative | 15.22M USD | 16.5M USD | 13.91M USD | 18.7M USD | 20.43M USD |
| Operating expenses | 85.31M USD | 48.12M USD | 45.08M USD | 33.35M USD | 55.23M USD |
| Interest income | 5.53M USD | 6.31M USD | — | — | — |
| Interest expense | — | 1.87M USD | 2.92M USD | 2.13M USD | 1.83M USD |
| Depreciation and amortization | 233K USD | 588K USD | 641K USD | 1.49M USD | 1.64M USD |
| Operating income | −85.31M USD | −48.72M USD | −45.08M USD | −34.84M USD | −55.99M USD |
| Net income | −78.54M USD | −40.21M USD | −44.6M USD | −55.83M USD | −45.55M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI5.82M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM2.4M0.00%77.7B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF2.16M0.00%95.4B USD0.05%$233.13-0.15%
Vanguard Russell 2000 ETFVTWO1.03M0.01%18B USD0.06%$112.1-0.10%
Dimensional - US Small Cap ETFDFAS543.77K0.00%33.66B USD0.31%$78.10+0.23%
Fidelity Enhanced Small Cap ETFFESM501.81K0.01%6.41B USD0.28%$45.25+0.07%
iShares Micro-Cap ETFIWC296.07K0.02%1.32B USD0.60%$182.79-0.31%
U.S. Micro Cap Portfolio ETFDFMC218.06K0.00%7.52B USD0.43%$57.70+0.35%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASFidelity Enhanced Small Cap ETFFESMiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
